BR112015017795A2 - antagonistas de kv1.3 e métodos de uso - Google Patents

antagonistas de kv1.3 e métodos de uso

Info

Publication number
BR112015017795A2
BR112015017795A2 BR112015017795A BR112015017795A BR112015017795A2 BR 112015017795 A2 BR112015017795 A2 BR 112015017795A2 BR 112015017795 A BR112015017795 A BR 112015017795A BR 112015017795 A BR112015017795 A BR 112015017795A BR 112015017795 A2 BR112015017795 A2 BR 112015017795A2
Authority
BR
Brazil
Prior art keywords
antagonists
methods
sequence
amino acid
acid sequence
Prior art date
Application number
BR112015017795A
Other languages
English (en)
Inventor
Wickenden Alan
Huang Chichi
Chi Ellen
swanson Ronald
Leung Wai-Ping
Edwards Wilson
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112015017795A2 publication Critical patent/BR112015017795A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Insects & Arthropods (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)

Abstract

resumo patente de invenção: "antagonistas de kv1.3 e métodos de uso". a presente invenção refere-se a antagonista de peptídeo isolado de kv1.3 tendo uma sequência de aminoácidos, compreendendo (i) a sequência mostrada na seq id no: 1 tendo uma substituição de glicina para isoleucina na posição 10 (g10i), e tendo opcionalmente 1, 2, 3, 4, 5, 6 ou 7 substituições adicionais; ou (ii) uma sequência de aminoácidos que é pelo menos 80% idêntica à seq id no: 1, compreendendo adicionalmente uma substituição de g10i. refere-se ainda a polinucleotídeos que codificam os ditos antagonistas, e métodos de preparo e uso dos anteriormente mencionados. 1/1
BR112015017795A 2013-01-25 2014-01-24 antagonistas de kv1.3 e métodos de uso BR112015017795A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756777P 2013-01-25 2013-01-25
US201361757389P 2013-01-28 2013-01-28
PCT/US2014/012932 WO2014116937A1 (en) 2013-01-25 2014-01-24 Kv1.3 antagonists and methods of use

Publications (1)

Publication Number Publication Date
BR112015017795A2 true BR112015017795A2 (pt) 2017-11-21

Family

ID=51228060

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015017795A BR112015017795A2 (pt) 2013-01-25 2014-01-24 antagonistas de kv1.3 e métodos de uso

Country Status (28)

Country Link
US (2) US10179808B2 (pt)
EP (1) EP2948559B1 (pt)
JP (1) JP6469590B2 (pt)
KR (1) KR102268830B1 (pt)
CN (1) CN104937105A (pt)
AU (1) AU2014209227B2 (pt)
BR (1) BR112015017795A2 (pt)
CA (1) CA2898496A1 (pt)
CY (1) CY1120481T1 (pt)
DK (1) DK2948559T3 (pt)
EA (1) EA037308B1 (pt)
ES (1) ES2671434T3 (pt)
HR (1) HRP20181055T1 (pt)
HU (1) HUE039465T2 (pt)
IL (1) IL239927B (pt)
LT (1) LT2948559T (pt)
MX (1) MX365987B (pt)
NZ (1) NZ709913A (pt)
PH (1) PH12015501627A1 (pt)
PL (1) PL2948559T3 (pt)
PT (1) PT2948559T (pt)
RS (1) RS57422B1 (pt)
SG (1) SG11201505508TA (pt)
SI (1) SI2948559T1 (pt)
TR (1) TR201809377T4 (pt)
UA (1) UA117824C2 (pt)
WO (1) WO2014116937A1 (pt)
ZA (1) ZA201506131B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023072A1 (en) * 2014-08-15 2016-02-18 Monash University Novel potassium channel blockers and use thereof in the treatment of autoimmune diseases
US10259122B2 (en) 2015-03-05 2019-04-16 President And Fellows Of Harvard College Compliant adaptive robot grasper
CA3022961A1 (en) 2016-05-02 2017-11-09 Tetragenetics, Inc. Anti-kv1.3 antibodies, and methods of production and use thereof
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
TW201808987A (zh) * 2016-06-08 2018-03-16 健生生物科技公司 Ｇｍ－ｃｓｆ變體及使用方法
CN106589092A (zh) * 2016-12-22 2017-04-26 中国科学技术大学先进技术研究院 一种蝎毒素多肽及制备拥有类似天然生理功能的蝎毒素多肽的方法
CN106957357B (zh) * 2017-04-01 2021-02-19 合肥科生景肽生物科技有限公司 一种蝎毒素多肽及其合成方法
EP4031162A1 (en) 2019-09-20 2022-07-27 Zealand Pharma A/S Kv1.3 blockers
AU2022245193A1 (en) 2021-03-23 2023-09-07 Zealand Pharma A/S Kv1.3 blockers
WO2024083919A1 (en) 2022-10-18 2024-04-25 Zealand Pharma A/S Inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
WO1999014318A1 (en) 1997-09-16 1999-03-25 Board Of Regents, The University Of Texas System Method for the complete chemical synthesis and assembly of genes and genomes
GB0414272D0 (en) 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
WO2006042151A2 (en) 2004-10-07 2006-04-20 The Regents Of The University Of California Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
AU2007343796A1 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
US8716437B2 (en) 2007-12-07 2014-05-06 Steven A. Goldstein Identification of toxin ligands
US20110236461A1 (en) 2008-08-13 2011-09-29 Underhill T Michael Methods for stimulating chondrogenesis utilizing a potassium channel inhibitor
CA2889453C (en) 2009-03-20 2018-11-06 Amgen Inc. Carrier immunoglobulins and uses thereof
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Also Published As

Publication number Publication date
US10179808B2 (en) 2019-01-15
CN104937105A (zh) 2015-09-23
ZA201506131B (en) 2017-06-28
WO2014116937A1 (en) 2014-07-31
TR201809377T4 (tr) 2018-07-23
HRP20181055T1 (hr) 2018-09-07
MX2015009632A (es) 2015-11-30
AU2014209227A1 (en) 2015-07-30
LT2948559T (lt) 2018-06-25
PT2948559T (pt) 2018-07-24
AU2014209227B2 (en) 2017-11-23
PH12015501627B1 (en) 2015-09-21
US20190062383A1 (en) 2019-02-28
RS57422B1 (sr) 2018-09-28
EP2948559B1 (en) 2018-05-02
IL239927B (en) 2020-10-29
NZ709913A (en) 2019-05-31
KR102268830B1 (ko) 2021-06-24
KR20150108912A (ko) 2015-09-30
EP2948559A1 (en) 2015-12-02
EA201591380A1 (ru) 2015-12-30
PL2948559T3 (pl) 2018-09-28
HUE039465T2 (hu) 2019-01-28
EP2948559A4 (en) 2016-10-19
MX365987B (es) 2019-06-20
SG11201505508TA (en) 2015-08-28
JP2016505639A (ja) 2016-02-25
IL239927A0 (en) 2015-08-31
DK2948559T3 (en) 2018-05-28
ES2671434T3 (es) 2018-06-06
SI2948559T1 (en) 2018-08-31
JP6469590B2 (ja) 2019-02-13
CA2898496A1 (en) 2014-07-31
EA037308B1 (ru) 2021-03-10
PH12015501627A1 (en) 2015-09-21
CY1120481T1 (el) 2019-07-10
UA117824C2 (uk) 2018-10-10
US20140255401A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
BR112015017795A2 (pt) antagonistas de kv1.3 e métodos de uso
CY1123100T1 (el) Μεθοδος για την παρασκευη amg 416
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
BR112018008918A8 (pt) compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
BR112014027165A2 (pt) antagonistas de st2l e métodos de uso
BR112016028066A2 (pt) composição de vacina; idessuis; ridessuis; anticorpo; composição parenteral; uso de uma proteína idessuis ou ridessuis; e célula hospedeira
BR112015027288A8 (pt) uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit
BR112013033671A2 (pt) composições de polipeptídeo de fusão fc livre de arginina e métodos de uso
BR112016014969A2 (pt) polipeptídeo, formulação farmacêutica e uso de um polipeptídeo
BR112016001036A2 (pt) fusocinas envolvendo citocinas com afinidades de ligação de receptores fortemente reduzida
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
BR112016024494A8 (pt) análogo de peptídeo e seu uso
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
BR112013011184A2 (pt) composições e métodos para tratamento de mielofibrose
BR112018011008A2 (pt) agonistas de cnp de liberação controlada com ligação a npr-c baixa
BR112017019625A2 (pt) udp-glicosiltransferases
BR112018006368A2 (pt) composição para desempenho melhorado
BR112014024751A2 (pt) antígenos de clostridium difficile
CO7131365A2 (es) Factores de coagulación de acción prolongada y métodos de producción de los mismos
BR112016012268A2 (pt) Composição aglutinante para argamassas e revestimentos, seu uso e sistema de revestimentos e argamassas
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
BR112015000583A2 (pt) proteínas reticuladas hipo-alergênicas para uso na prevenção de uma alergia à proteínas do leite e para uso na indução de tolerância oral
BR112015018265A2 (pt) Composições nutricionais contendo um componente peptídico com propriedades estimulantes de adiponectina e utilizações das mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2706 DE 16-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.